MSLE
Healthcare BiotechnologySatellos Bioscience Inc.
$8.50
+0.00 +0.00% today
Price History
Not enough data
Key Stats
Market Cap
180.34M
Avg Volume
58,620
EPS
-$1.95
52W High
$13.40
52W Low
$5.30
Div. Yield
0.0%
Analyst Ratings
Buy0
Str Buy
5
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-3.12
P/B Ratio
2.96
EV/EBITDA
-3.31
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(70.4%)
Return on Assets
(41.9%)
Liquidity & Leverage
Current Ratio
11.22
Quick Ratio
10.69
Total Cash
61.84M
Total Debt
0
About
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
satellos.com